Why the Injection Is a Game Changer
A newly approved twice‑annual injection could transform HIV prevention, but millions of people still cannot obtain it. The drug, described by experts as the closest thing to an HIV vaccine, delivers a potent antiretroviral that remains effective for months, promising a simple and reliable protection strategy.
The injection, developed by a major pharmaceutical company, was approved by regulatory agencies in 2021 after clinical trials showed a 90% reduction in new infections. It works by maintaining steady drug levels in the bloodstream, eliminating the need for daily pills. However, the cost of the medication and the limited manufacturing capacity have kept it out of reach for many high‑risk populations, especially in low‑income countries.
Unlike daily oral pre‑exposure prophylaxis, the long‑acting injection requires only two doses per year. Patients receive the shot in a clinic, and the drug stays in the body for six months, providing continuous protection. This schedule improves adherence, a major challenge with daily medication. Health workers report fewer missed doses and lower rates of resistance. Side effects are mild, with most patients experiencing only local soreness at the injection site.
Who Is Left Behind? Access Gaps and Cost Hurdles
Because the drug mimics the immune response of a vaccine, it has attracted attention from global health organizations. It could be a powerful tool in regions where HIV transmission remains high and daily pill adherence is low. In pilot programs, the injection has shown the potential to reduce new infections among men who have sex with men, sex workers, and people who inject drugs.
The main barrier is price. The manufacturer sets a list price that is several times higher than daily oral pre‑exposure prophylaxis. In many countries, insurance plans do not cover the injection, and government procurement budgets are limited. Supply chain constraints also play a role; the drug requires cold‑chain storage and trained personnel to administer shots, which are scarce in rural areas.
The World Health Organization has recommended the injection for high‑risk groups, but national programs have been slow to adopt it. Some high‑income countries have begun offering it through specialized clinics, while low‑ and middle‑income nations struggle to secure funding and distribution agreements. Negotiations with the manufacturer and potential price‑reduction agreements are underway, but progress is uneven.
The consequences of unequal access are significant. Communities that cannot obtain the injection remain vulnerable to new HIV infections, undermining global elimination targets. If the drug is adopted widely, it could accelerate progress toward ending the epidemic. However, without affordable and widespread availability, the promise of the injection will remain limited.
Frequently Asked Questions
What is the name of the drug? The injection is called cabotegravir, a long‑acting antiretroviral developed by a leading pharmaceutical company.
How often must it be given? Patients receive the shot twice a year, typically every six months, to maintain protective drug levels.
Will it replace daily pills? While the injection offers a convenient alternative, it is not intended to replace all daily pre‑exposure prophylaxis. It is most suitable for individuals who struggle with daily adherence or prefer a less frequent dosing schedule.